Schering Corporation

Acquist LLC

Usv Pharmaceutical Corporation

Merck Sharp + Dohme Corp.

Southern Research Institute

Other

John J. Piwinski

Jesse Wong

Michael J. Green

John J Piwinski

Neng-Yang Shih

F George Njoroge

Jesse K Wong

Michael J Green

Ronald L Wolin

Ronald J Doll

Alan K Mallams

Robert G Aslanian

Kevin D McCormick

Joanne M Petrin

Arthur G Taveras

Stacy W Remiszewski

David J Blythin

Ho-Jane Shue

Xiao Chen

W Robert Bishop

Ashit K Ganguly

Raymond P Warrell, Jr

John T Suh

Richard J Friary

Howard Jones

Pauline C Ting

Daniel M Solomon

Arshad Siddiqui

Stuart B Rosenblum

Wing C Tom

Edward S Neiss

Frank J Villani

John A Secrist, Iii

Subramaniam Ananthan

Pietro Mangiaracina

Gregory A Reichard

Joseph A Maddry

Feng Geng

Paul R Menard

Robert C Reynolds

Cecil D Kwong

Alexandre Larivée

Hollis S Kezar, Iii

Jeremy Clark

Abhijit Roychowdhury

Andrew Lupo, Jr

Frank W Bennett

John R Regan

Ashok Arasappan

Dong Xiao

Wayne D Vaccaro

Michael Berlin

Bandarpalle B Shankar

Christopher W Boyce

Sunil Paliwal

Andrew T Lupo

Mwangi W Mutahi

Vera A Seidl

Nicholas I Carruthers

Joe F Lee

Michael P Kirkup

James M Spitler

Anita T Fowler

Mwangi Wa Mutahi

Cheryl A Alaimo

Ronald N Buckle

Karen Thai

Robert W Bishop

Adriano Afonso

Srikanth Venkatraman

Jerry W Skiles

Vinay M Girijavallabhan

Francisco Velazquez

Vishal Verma

Yuhua Huang

Dhiru B Vashi

James P Jakway

Regina Huelgas

Jeffrey Cramer

Bernard Katchen

Tom G Wing

John A Secrist

Hollis S Kezar

Iii Hollis S Kezar

Iii John A Secrist

Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders of uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.

Compounds and their use for reducing uric acid levels

Bifunctional barbiturate-derivative compounds that increase uric acid excretion and reduce uric acid production, and monofunctional barbiturate-derivative compounds that either increase uric acid excretion or reduce uric acid production are provided. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders associated with excess uric acid, and for maintaining normal uric acid levels in blood or serum, or the whole body, are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.

Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders or uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.

Bifunctional compounds and use for reducing uric acid levels

Bifunctional compounds that increase uric acid excretion and reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders or uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are provided. Pharmaceutical compositions comprising the bifunctional compounds are also provided.

The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, R, R, R, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and pro-drugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, R, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders. 

AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

Disclosed are novel compounds of the formula  Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a Hreceptor antagonist.

Non-imidazole compounds

The present invention discloses novel substituted imidazole compounds which have H receptor antagonist or dual histamine-H and H receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.

Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists

Growing community of inventors

Lebanon, NJ, United States of America

John J Piwinski